Human Tissue Authority

The regulator for human tissue and organs

Stem cell coordinators and Specialist Nurses

The use of video conferencing platforms

We are supporting the use of video conferencing for interviews during this period of time. Equally, if you feel that your hospital can safely facilitate face to face interviews in line with Government guidance, then that is a decision for you and colleagues to make. 

We have communicated this to AAs, but please be aware that some may have concerns about conducting face to face interviews during the present conditions.

We have sent guidance to AAs to help support video conference moving forward. 

The video conferencing facility that is used must be supported by your local hospital protocol and security. We advise using a platform that allows for more than one participant where possible to allow for a joint interview. This means it needs to have the functionality to speak and see more than one person at a time. Please discuss the practicalities with the AA if your hospital has a preferred or existing local platform that they will need to use.  


Logistics such as how to access the video platform will need to be agreed between you and the AA i.e. account details and the use of personal equipment where applicable.  

You will need to ensure that the parents or person consenting has access to the agreed video platform, and these details will need to be communicated to those involved prior to the interview.

Young recipients or recipients who are too unwell to be interviewed

In instances where the donor or recipient is too young (or pre-verbal) to be interviewed, or the recipient is too ill to be interviewed, we have asked AAs to follow the same guidelines in place for face to face interviews.

COVID-19 risks

Moving forward

It is important that patients are aware of any additional risks relating to COVID-19.

Please ensure you confirm that these risks have been discussed with the donor, the recipient and the person consenting on behalf of the donor within referral letter for the foreseeable future. This includes confirming that the donor, the recipient and the person consenting on behalf of the donor have been told about any measures the clinical team have taken to minimise the risks surrounding COVID-19. 

AAs have been asked to clearly document the discussion they have had with those involved to check the understanding of these risks within their report to the HTA.

We understand there will be ongoing questions about the changes we have outlined above however please be assured that we are here to support you. If you have any questions please don’t hesitate to contact the team on

Last updated on: 24 Sep 2020